HRP20171431T1 - Terapijska parenteralna primjena krilovog ulja - Google Patents
Terapijska parenteralna primjena krilovog ulja Download PDFInfo
- Publication number
- HRP20171431T1 HRP20171431T1 HRP20171431TT HRP20171431T HRP20171431T1 HR P20171431 T1 HRP20171431 T1 HR P20171431T1 HR P20171431T T HRP20171431T T HR P20171431TT HR P20171431 T HRP20171431 T HR P20171431T HR P20171431 T1 HRP20171431 T1 HR P20171431T1
- Authority
- HR
- Croatia
- Prior art keywords
- intended
- omega
- amount
- accordance
- oil
- Prior art date
Links
- 229940106134 krill oil Drugs 0.000 title claims 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 11
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 150000003904 phospholipids Chemical class 0.000 claims 8
- 150000003626 triacylglycerols Chemical class 0.000 claims 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 6
- 235000021323 fish oil Nutrition 0.000 claims 6
- 239000003921 oil Substances 0.000 claims 6
- 235000019198 oils Nutrition 0.000 claims 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 5
- 241000239366 Euphausiacea Species 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 3
- 239000007764 o/w emulsion Substances 0.000 claims 3
- 239000006014 omega-3 oil Substances 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 2
- -1 omega-3 fatty acid triglycerides Chemical class 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Farmaceutski pripravak koji se može primijeniti parenteralno, koji sadrži emulziju ulja u vodi koja sadrži fosfolipid dobiven iz morskog raka, naznačen time što je namijenjen upotrebi u liječenju endotoksikoze prilikom sepse ili, što je namijenjen upotrebi u liječenju osobe s toksičnim razinama visokolipofilnih lijekova u krvi.
2. Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je morski rak kril (Euphausiacea).
3. Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što pripravak sadrži fosfolipid dobiven iz krila u količini koja se kreće u rasponu od 0,05 g/l do 100 g/l, po mogućnosti 0,1 do 50 g/l, poželjnije 0,5 do 30 g/l, osobito 5 do 20 g/l, na osnovi ukupnog farmaceutskog pripravka.
4. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 3, naznačen time što fosfolipidi koji sadrže omega-3 masne kiseline sadrže DHA u količini od otprilike 10 do otprilike 20%, težinski, na osnovi ukupne težine sadržaja masnih kiselina u fosfolipidima.
5. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 4, naznačen time što fosfolipidi koji sadrže omega-3 masne kiseline sadrže EPA u količini od otprilike 20 do otprilike 40%, težinski, na osnovi ukupne težine sadržaja masnih kiselina u fosfolipidima.
6. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 5, naznačen time što se omjer težine između ulja i vode emulziji ulja u vodi kreće od otprilike 1:99 do otprilike 20:80.
7. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 6, naznačen time što je pripravak emulzija ulja u vodi, koja sadrži:
a) fosfolipid dobiven iz krila,
b) riblje ulje, po mogućnosti ono visoko obogaćeno omega-3 masnokiselinskom komponentom, koja sadrži najmanje 45%, težinski, EPA i DHA
c) vodu,
d) izborno srednjedugolančane trigliceride i
e) izborno antioksidans.
8. Farmaceutski pripravak, kao pripravak za parenteralnu primjenu, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 7, naznačen time što sadrži
a) omega-3-masnokiselinsku komponentu, koju se bira iz skupine koju čine omega-3-masnokiselinski trigliceridi i/ili esteri omega-3-masnih kiselina, poput etilnog estera omega-3 masnih kiselina.
9. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 8, naznačen time što pripravak sadrži omega-3-masnokiselinske trigliceride i srednjedugolančane trigliceride (MCT).
10. Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što emulzija sadrži 10 do 69%, težinski, MCT, na osnovi ukupne količine uljne komponente u emulziji.
11. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 10, naznačen time što emulzija sadrži uljnu komponentu i vodenu komponentu, gdje uljna komponenta sadrži trigliceride ribljeg ulja u količini od otprilike 60% do otprilike 90% na osnovi težine uljne komponente; gdje trigliceridi ribljeg ulja sadrže omega-3 masne kiseline u količini od najmanje 60%, na osnovi ukupne težine masnih kiselina u trigliceridima ribljeg ulja; gdje trigliceridi ribljeg ulja sadrže ukupnu količinu EPA i DHA od najmanje 45%, na osnovi ukupne težine masnih kiselina u trigliceridima ribljeg ulja; te, najmanje jedan srednjedugolančani triglicerid, gdje se ukupna količina najmanje jednog srednjedugolančanog triglicerida kreće od otprilike 10% do otprilike 40% na osnovi težine uljne komponente.
12. Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što omega-3-masnokiselinska komponenta sadrži ikozapentaensku kiselinu u količini od 30% ili većoj, dokozaheksaensku kiselinu u količini od 30% ili manjoj, te dokozapentaensku kiselinu u količini od otprilike 40% ili manjoj, na osnovi težine ukupnog sadržaja omega-3 masnih kiselina.
13. Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je namijenjen upotrebi u liječenju svakodnevnom parenteralnom primjenom navedene omega-3 masne kiseline u količini od otprilike 1 do otprilike 300 mg/kg.
14. Farmaceutski pripravak, namijenjen upotrebi u skladu s jednim ili više patentnih zahtjeva od 1 do 13, naznačen time što je krilovo ulje prisutno u količini od otprilike 1% do otprilike 20%, na osnovi ukupne težine pripravka.
15. Krilovi fosfolipidi, naznačeni time što su namijenjeni upotrebi u liječenju endotoksikoze kod sepse.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/161,101 US8895074B2 (en) | 2011-06-15 | 2011-06-15 | Therapeutic application of parenteral krill oil |
| EP11179821 | 2011-09-02 | ||
| EP12731667.7A EP2720701B1 (en) | 2011-06-15 | 2012-06-13 | Therapeutic application of parenteral krill oil |
| PCT/IB2012/001156 WO2012172411A1 (en) | 2011-06-15 | 2012-06-13 | Therapeutic application of parenteral krill oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171431T1 true HRP20171431T1 (hr) | 2017-12-15 |
Family
ID=46456944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171431TT HRP20171431T1 (hr) | 2011-06-15 | 2017-09-21 | Terapijska parenteralna primjena krilovog ulja |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2720701B1 (hr) |
| JP (1) | JP5864735B2 (hr) |
| KR (1) | KR101841588B1 (hr) |
| CN (2) | CN103608023A (hr) |
| BR (1) | BR112013032224B1 (hr) |
| CA (1) | CA2838312C (hr) |
| CY (1) | CY1119417T1 (hr) |
| DK (1) | DK2720701T3 (hr) |
| ES (1) | ES2643843T3 (hr) |
| HR (1) | HRP20171431T1 (hr) |
| HU (1) | HUE036720T2 (hr) |
| IL (1) | IL229690A (hr) |
| LT (1) | LT2720701T (hr) |
| MX (1) | MX351895B (hr) |
| PL (1) | PL2720701T3 (hr) |
| PT (1) | PT2720701T (hr) |
| RS (1) | RS56394B1 (hr) |
| RU (1) | RU2625760C2 (hr) |
| SI (1) | SI2720701T1 (hr) |
| TW (1) | TWI592160B (hr) |
| WO (1) | WO2012172411A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993980B1 (en) * | 2013-05-10 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Lipid scavenging in ras cancers |
| GB201402450D0 (en) | 2014-02-12 | 2014-03-26 | Aker Biomarine As | Liquid phospholipid-containing compositions for preperation of pharmaceuticals |
| GB201402457D0 (en) | 2014-02-12 | 2014-03-26 | Aker Biomarine As | Capsules containing high doses of phospholipids |
| GB201407345D0 (en) | 2014-04-25 | 2014-06-11 | Aker Biomarine As | Krill Phospholipid compositions |
| EP3137070B1 (en) | 2014-04-30 | 2020-04-15 | Aker BioMarine Antarctic AS | Krill oil preparations and their uses |
| US11147841B2 (en) | 2014-12-19 | 2021-10-19 | Aker Biomarine Antarctic As | Enhanced omega-3 formulations |
| EP3277262A1 (en) * | 2015-03-31 | 2018-02-07 | Fresenius Kabi Deutschland GmbH | Emulsions for parenteral administration |
| CN105901740A (zh) * | 2016-04-26 | 2016-08-31 | 济南极源生物科技有限公司 | 一种南极磷虾油可食用营养品 |
| EP3664628A4 (en) * | 2017-08-10 | 2021-04-14 | The Children's Medical Center Corporation | PROCESSES AND COMPOSITIONS RELATING TO EMULSIONS CONTAINING FISH OIL AND / OR OMEGA-3 FATTY ACIDS |
| EP3536332A1 (en) * | 2018-03-07 | 2019-09-11 | Athenion AG | Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents |
| KR102451162B1 (ko) * | 2020-09-07 | 2022-10-06 | (주)에스디생명공학 | 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9101642D0 (sv) * | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
| JPH08231391A (ja) * | 1995-02-24 | 1996-09-10 | Kanagawa Kagaku Kenkyusho:Kk | 痴呆症状改善薬 |
| EP1039893B1 (en) * | 1997-12-10 | 2011-02-02 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| GB0012597D0 (en) * | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
| PT1406641E (pt) * | 2001-06-18 | 2009-04-15 | Neptune Technologies & Bioress | Extractos de krill para prevenção e/ou tratamento de doenças cardiovasculares |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| CN101321477A (zh) * | 2005-10-07 | 2008-12-10 | 加拿大海洋营养食品有限公司 | 脂肪酸盐及其制备和使用方法 |
| RU2458112C2 (ru) * | 2006-11-16 | 2012-08-10 | Пронова Биофарма Норге Ас | Способ получения богатых омега-3 жирными кислотами морских фосфолипидов из криля |
| WO2008117062A1 (en) * | 2007-03-28 | 2008-10-02 | Aker Biomarine Asa | Bioeffective krill oil compositions |
| US20110065673A1 (en) * | 2007-05-11 | 2011-03-17 | Bizen Chemical Co., Ltd. | Novel leukotriene receptor agonist |
| NO327925B1 (no) * | 2007-06-25 | 2009-10-19 | Pharmalogica As | Anvendelse av kullsyre i drikker omfattende polyumettede fettsyrer (PUFA) for a hindre oksidasjon av fettsyrene. |
| US20090099261A1 (en) * | 2007-09-25 | 2009-04-16 | Isi Brands Inc. | Omega-3 mixtures |
| US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
| US20100130619A1 (en) * | 2008-11-24 | 2010-05-27 | Joseph Schwarz | Pharmaceutical composition for parenteral administration of idebenone |
| US8241672B2 (en) * | 2009-03-11 | 2012-08-14 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
| US20110071090A1 (en) * | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
| NO333013B1 (no) * | 2009-07-06 | 2013-02-18 | Smartfish As | Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning. |
| US8609157B2 (en) * | 2009-10-30 | 2013-12-17 | Tharos Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
-
2012
- 2012-06-13 DK DK12731667.7T patent/DK2720701T3/en active
- 2012-06-13 ES ES12731667.7T patent/ES2643843T3/es active Active
- 2012-06-13 MX MX2013014901A patent/MX351895B/es active IP Right Grant
- 2012-06-13 RS RS20170981A patent/RS56394B1/sr unknown
- 2012-06-13 HU HUE12731667A patent/HUE036720T2/hu unknown
- 2012-06-13 EP EP12731667.7A patent/EP2720701B1/en active Active
- 2012-06-13 LT LTEP12731667.7T patent/LT2720701T/lt unknown
- 2012-06-13 JP JP2014515299A patent/JP5864735B2/ja not_active Expired - Fee Related
- 2012-06-13 KR KR1020147001111A patent/KR101841588B1/ko active IP Right Grant
- 2012-06-13 CN CN201280028987.7A patent/CN103608023A/zh active Pending
- 2012-06-13 WO PCT/IB2012/001156 patent/WO2012172411A1/en active Application Filing
- 2012-06-13 SI SI201231091T patent/SI2720701T1/sl unknown
- 2012-06-13 PL PL12731667T patent/PL2720701T3/pl unknown
- 2012-06-13 CA CA2838312A patent/CA2838312C/en not_active Expired - Fee Related
- 2012-06-13 BR BR112013032224-1A patent/BR112013032224B1/pt not_active IP Right Cessation
- 2012-06-13 PT PT127316677T patent/PT2720701T/pt unknown
- 2012-06-13 CN CN201710990052.1A patent/CN107648268B/zh not_active Expired - Fee Related
- 2012-06-13 RU RU2014101067A patent/RU2625760C2/ru active
- 2012-06-15 TW TW101121508A patent/TWI592160B/zh not_active IP Right Cessation
-
2013
- 2013-11-28 IL IL229690A patent/IL229690A/en active IP Right Grant
-
2017
- 2017-09-21 HR HRP20171431TT patent/HRP20171431T1/hr unknown
- 2017-10-04 CY CY20171101030T patent/CY1119417T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1119417T1 (el) | 2018-03-07 |
| LT2720701T (lt) | 2017-11-10 |
| PL2720701T3 (pl) | 2018-01-31 |
| TWI592160B (zh) | 2017-07-21 |
| RU2625760C2 (ru) | 2017-07-18 |
| RS56394B1 (sr) | 2017-12-29 |
| HUE036720T2 (hu) | 2018-07-30 |
| KR101841588B1 (ko) | 2018-03-26 |
| BR112013032224A2 (pt) | 2016-12-20 |
| IL229690A0 (en) | 2014-01-30 |
| IL229690A (en) | 2017-01-31 |
| DK2720701T3 (en) | 2017-10-30 |
| WO2012172411A1 (en) | 2012-12-20 |
| JP2014517028A (ja) | 2014-07-17 |
| SI2720701T1 (sl) | 2017-12-29 |
| MX2013014901A (es) | 2014-07-09 |
| BR112013032224B1 (pt) | 2021-10-13 |
| JP5864735B2 (ja) | 2016-02-17 |
| CN107648268A (zh) | 2018-02-02 |
| CA2838312C (en) | 2019-01-08 |
| CN103608023A (zh) | 2014-02-26 |
| ES2643843T3 (es) | 2017-11-24 |
| TW201302209A (zh) | 2013-01-16 |
| CN107648268B (zh) | 2021-06-22 |
| PT2720701T (pt) | 2017-10-23 |
| MX351895B (es) | 2017-11-01 |
| KR20140053957A (ko) | 2014-05-08 |
| EP2720701A1 (en) | 2014-04-23 |
| RU2014101067A (ru) | 2015-07-20 |
| CA2838312A1 (en) | 2012-12-20 |
| EP2720701B1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171431T1 (hr) | Terapijska parenteralna primjena krilovog ulja | |
| HRP20200068T1 (hr) | Etilni ester ikozapentaenske kiseline, namijenjen liječenju hipertrigliceridemije | |
| RU2014138996A (ru) | Гормонсодержащая эмульсия | |
| HRP20210309T1 (hr) | Postupci za smanjivanje rizika kardiovaskularnih slučajeva kod pojedinca na statinskoj terapiji uporabom etilestera eikosapentaenoične kiseline | |
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| RU2011141102A (ru) | Обогащенные омега-3 рыбные парентеральные питательные эмульсии типа масло в воде | |
| US20070122452A1 (en) | Fat composition | |
| JP2014517028A5 (hr) | ||
| HRP20161272T4 (hr) | Učinci metaboličkog utiskivanja specifično dizajnirane lipidne komponente | |
| JP2012502090A5 (hr) | ||
| NZ626699A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| WO2006111633A3 (fr) | Utilisation de la lecithine comme medicament dans le traitement du psoriasis | |
| JP2014231513A5 (hr) | ||
| RU2017118984A (ru) | Молочная смесь, содержащая олигосахариды грудного молока, полиненасыщенные жирные кислоты, нуклеотиды и лютеин | |
| RU2013146517A (ru) | Композиции и способы, пригодные для облегчения возрастных заболеваний | |
| Vázquez et al. | Bioactive lipids | |
| WO2011137160A3 (en) | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans | |
| JP2020530464A5 (hr) | ||
| RU2016129079A (ru) | Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы | |
| JP2012508791A5 (hr) | ||
| UA111967C2 (uk) | Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання | |
| WO2018066394A1 (ja) | 筋肉を柔軟にするための組成物 | |
| Zhang | Omega-3 phospholipids | |
| JP6519875B2 (ja) | 改良された魚油ベースのオメガ３補助食品 | |
| Abdel-Halim et al. | Effect of flaxseed and corn oils on acute myocardial infarction in high fat diet fed rat |